TY  - JOUR
AU  - Perkovic, Vlado
AU  - Jardine, Meg J
AU  - Neal, Bruce
AU  - Bompoint, Severine
AU  - Heerspink, Hiddo J L
AU  - Charytan, David M
AU  - Edwards, Robert
AU  - Agarwal, Rajiv
AU  - Bakris, George
AU  - Bull, Scott
AU  - Cannon, Christopher P
AU  - Capuano, George
AU  - Chu, Pei-Ling
AU  - de Zeeuw, Dick
AU  - Greene, Tom
AU  - Levin, Adeera
AU  - Pollock, Carol
AU  - Wheeler, David C
AU  - Yavin, Yshai
AU  - Zhang, Hong
AU  - Zinman, Bernard
AU  - Meininger, Gary
AU  - Brenner, Barry M
AU  - Mahaffey, Kenneth W
AU  - CREDENCE Trial Investigators
PY  - 2019
DO  - 10.1056/NEJMoa1811744
UR  - https://hdl.handle.net/10668/26680
T2  - The New England journal of medicine
AB  - Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that...
LA  - en
KW  - Aged
KW  - Canagliflozin
KW  - Cardiovascular Diseases
KW  - Creatinine
KW  - Diabetes Mellitus, Type 2
KW  - Diabetic Nephropathies
KW  - Double-Blind Method
KW  - Female
KW  - Follow-Up Studies
KW  - Glomerular Filtration Rate
KW  - Humans
KW  - Kidney Failure, Chronic
KW  - Male
KW  - Middle Aged
KW  - Sodium-Glucose Transporter 2 Inhibitors
TI  - Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
TY  - research article
VL  - 380
ER  -